CN114008075A - 人源化抗vegf单克隆抗体 - Google Patents

人源化抗vegf单克隆抗体 Download PDF

Info

Publication number
CN114008075A
CN114008075A CN202080046296.4A CN202080046296A CN114008075A CN 114008075 A CN114008075 A CN 114008075A CN 202080046296 A CN202080046296 A CN 202080046296A CN 114008075 A CN114008075 A CN 114008075A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
vegf
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080046296.4A
Other languages
English (en)
Inventor
谢良志
孙春昀
汪瑞
张潇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinocelltech Ltd
Original Assignee
Sinocelltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinocelltech Ltd filed Critical Sinocelltech Ltd
Publication of CN114008075A publication Critical patent/CN114008075A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

本发明属于肿瘤免疫治疗领域，涉及一种结合VEGF的人源化单克隆抗体。本发明公开编码所述抗体的核酸序列(包括重/轻链可变区)、含有所述核酸序列的载体、药物组合物和试剂盒。本发明公开的抗体可以高亲和力的特异性结合VEGF，并阻断VEGF与受体VEGFR2的结合。所述抗体还能中和VEGF165单独及多种VEGF亚型共同对HUVEC细胞的增殖作用，可用于临床治疗肿瘤，包括但不限于：结直肠癌。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN202080046296.4A 2019-07-19 2020-07-17 人源化抗vegf单克隆抗体 Pending CN114008075A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019106574977 2019-07-19
CN201910657497 2019-07-19
PCT/CN2020/102622 WO2021013080A1 (zh) 2019-07-19 2020-07-17 人源化抗vegf单克隆抗体

Publications (1)

Publication Number Publication Date
CN114008075A true CN114008075A (zh) 2022-02-01

Family

ID=74193255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046296.4A Pending CN114008075A (zh) 2019-07-19 2020-07-17 人源化抗vegf单克隆抗体

Country Status (10)

Country Link
US (1) US20220144930A1 (zh)
EP (1) EP4001306A4 (zh)
JP (1) JP7352007B2 (zh)
KR (1) KR20220071177A (zh)
CN (1) CN114008075A (zh)
AU (1) AU2020316498B2 (zh)
BR (1) BR112022001017A2 (zh)
CA (1) CA3147921C (zh)
MX (1) MX2022000779A (zh)
WO (1) WO2021013080A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850470A (zh) * 2022-12-12 2023-03-28 三门峡市眼科医院 Vegf抗体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230142838A (ko) * 2021-02-10 2023-10-11 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 항-vegf 항체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820245A (zh) * 2015-01-06 2016-08-03 珠海亿胜生物制药有限公司 抗vegf抗体
WO2017119435A1 (ja) * 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ 高親和性抗ｖｅｇｆ抗体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN103755809B (zh) * 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
ES2923641T3 (es) * 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
CN108101985B (zh) * 2015-01-06 2020-04-10 珠海亿胜生物制药有限公司 抗vegf抗体
JP7229419B2 (ja) * 2019-07-19 2023-02-27 神州細胞工程有限公司 ヒト化抗ｖｅｇｆ ｆａｂ抗体断片及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820245A (zh) * 2015-01-06 2016-08-03 珠海亿胜生物制药有限公司 抗vegf抗体
WO2017119435A1 (ja) * 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ 高親和性抗ｖｅｇｆ抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KONG,D.H.等: "A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCE, vol. 18, pages 1 - 25, XP055776060, DOI: 10.3390/ijms18081786 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850470A (zh) * 2022-12-12 2023-03-28 三门峡市眼科医院 Vegf抗体及其应用
CN115850470B (zh) * 2022-12-12 2023-07-07 三门峡市眼科医院 Vegf抗体及其应用

Also Published As

Publication number Publication date
AU2020316498B2 (en) 2024-02-29
KR20220071177A (ko) 2022-05-31
MX2022000779A (es) 2022-02-14
JP7352007B2 (ja) 2023-09-27
AU2020316498A1 (en) 2022-02-03
EP4001306A4 (en) 2023-11-15
EP4001306A1 (en) 2022-05-25
US20220144930A1 (en) 2022-05-12
WO2021013080A1 (zh) 2021-01-28
BR112022001017A2 (pt) 2022-04-12
JP2022542037A (ja) 2022-09-29
CA3147921A1 (en) 2021-01-28
CA3147921C (en) 2023-02-21

Similar Documents

Publication Publication Date Title
CA3080120C (en) Anti-galectin-9 antibodies and uses thereof
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
WO2017049452A1 (zh) 抗人cd137的完全人抗体及其应用
CN114127106B (zh) 人源化抗VEGF Fab抗体片段及其用途
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
KR20200063153A (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
CA3043691A1 (en) Antibody binding specifically to cd66c and use thereof
US20220144930A1 (en) Humanized Anti-VEGF Monoclonal Antibody
JP2023166403A (ja) Ｐｄｌ１を標的とする抗体及びそれを用いる方法
CN114174335B (zh) 一种人源化vegfr2抗体及其应用
CN114667296B (zh) 一种双特异性抗体及其用途
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
CN114144431B (zh) 人源化抗TNFα抗体及其用途
RU2809746C2 (ru) Гуманизированное моноклональное антитело против vegf
KR20210076907A (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
CN114341170B (zh) 一种人源化抗vegfr2抗体及其应用
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
CA3231320A1 (en) Protein specifically binding to pd-1 and pharmaceutical use thereof
CA3209827A1 (en) Anti-tnfr2 antibody and use thereof
CN117940453A (zh) 特异性结合pd-1的蛋白及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066231

Country of ref document: HK